Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma
Authors:
- S. BorgSBS. Borg
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 100 (4) , 586-594
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Asthma: prevalence and cost of illnessEuropean Respiratory Journal, 2005
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004
- Low Dose Inhaled Budesonide and Formoterol in Mild Persistent AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Trends in the cost of illness for asthma in the United States, 1985-1994Journal of Allergy and Clinical Immunology, 2000
- Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/500??g vs Fluticasone Propionate 500??g in Patients with Corticosteroid-Dependent Asthma V: ResultsPharmacoEconomics, 1999
- Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/250??g vs Fluticasone Propionate 250??g in Adults and Adolescents with Asthma IV: ResultsPharmacoEconomics, 1999
- Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/100??g vs Fluticasone Propionate 100??g in Adults and Adolescents with Asthma III: ResultsPharmacoEconomics, 1999
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Statistical analysis of cost outcomes in a randomized controlled clinical trialHealth Economics, 1994
- The Episode-Free Day as a Composite Measure of EffectivenessPharmacoEconomics, 1993